Coronary Artery Diseases
Conditions
Brief summary
Registry of cilotax stent(Dual drug eluting stent) implantation for CAD patients
Interventions
None listed
Sponsors
CardioVascular Research Foundation, Korea
Cardiotec Corporation
Seung-Jung Park
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with significant coronary artery disease and receiving Cilotax (dual drug eluting stent) * The patient or guardian agrees to the study protocol and the schedule of clinical follow-up, and provides informed, written consent, as approved by the appropriate Institutional Review Board/Ethics Committee of the respective clinical site
Exclusion criteria
* Patients with a mixture of other DESs * Terminal illness with life expectancy \<1 year * Patients presented with cardiogenic shock
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| composite of death, nonfatal myocardial infarction (MI), or target- Vessel Revascularization (TVR) | at 12 months post procedure |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Myocardial Infarction | 12 months and yearly up to 5 years | — |
| Composite of death or MI | 6 months | — |
| Composite of cardiac death or MI | one month | — |
| Death (all cause and cardiac) | one month | — |
| Target-lesion revascularization | one month | — |
| Stent thrombosis | 12 months and yearly up to 5 years | — |
| Procedural success | at day 1 | It is defined as achievement of a final diameter stenosis of \<30% by visual estimation, without the occurrence of death, Q-wave MI, or urgent revascularization during the index hospitalization. |
| Target Vessel Revascularization | 12 months and yearly up to 5 years | — |
Countries
South Korea
Outcome results
None listed